Search for a trial

Developing diagnostic criteria for the differentiation between large vessel vasculitis and atherosclerosis using 18FDG-PET/CT

To establish criteria that differentiate between large-vessel vasculitis and atherosclerosis as a cause of enhanced vascular 18-FDG uptake on 18-FDG-PET/CT.

Recovery of circadian rhythm of the hypothalamic-pituitary-adrenal axis during glucocorticoid tapering in ANCA-associated vasculitis, a pilot study

The primary aim of this study is to investigate the recovery of the circadian rhythm of the hypothalamic-pituitary-adrenal axis during a glucocorticoid tapering regime. Secondary objectives include the effect of a tapering regime on melatonin rhythm…

The RVCL-ID study - Identifying biomarkers and disease stages of Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL), a monogenic vascular migraine model

1. To identify presymptomatic and symptomatic profiles including (early) disease stages and early biomarkers of disease progression and to elucidate pathophysiological mechanisms, we will investigate RVCL patients at different ages (both symptomatic…

The effects of red blood cell transfusion on the microcirculation in chronic anemic preterm neonates.

To determine the effect of a single red blood cell transfusion on the microcirculation.

The RVCL-MRI study: neuroimaging findings and cerebrovascular reactivity in preclinical and clinical disease stages of Retinal Vasculopathy with Cerebral Leukodystrophy (RVCL), in migraine patients and healthy controls.

1. To assess neuroimaging hallmarks of RVCL disease stages;2. To evaluate cerebrovascular reactivity as a biomarker of endothelial (dys)function in RVCL patients, in migraine patients and healthy controls;3. To identify shared pathophysiological…

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

Primary ObjectiveThe primary objective is to evaluate the effectiveness of adding Epanova to statin therapy (with or without ezetimibe) for lowering MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, emergent/elective…